Pitavastatin

A new HMG-CoA reductase inhibitor for the treatment of hypercholesterolemia

Haniyyah Ahmad, Angela Cheng-Lai

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Because of their good tolerability and their positive effect on lipid parameters and clinical outcomes, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) have become the drugs of first choice for the management of dyslipidemia. Pitavastatin is the newest member in the statin family and received Food and Drug Administration approval for oral use in August 2009. Compared to other statins such as atorvastatin, simvastatin and pravastatin at specific doses, pitavastatin dosed at 1 to 4 mg daily showed similar efficacy in lowering low-density lipoprotein cholesterol (LDL-C) and altering other lipid parameters according to a number of studies. In addition, pitavastatin demonstrated cholesterol-lowering efficacy in special populations such as the elderly, patients with diabetes, and patients with higher cardiovascular risk. Because pitavastatin is minimally metabolized by the cytochrome P-450 isoenzymes, it is associated with a lower frequency of drug-drug interactions, and this may be a desirable characteristic of pitavastatin. Beneficial effects, such as reductions of coronary plaque volume and fibrofatty composition, have also been observed with pitavastatin. Thus far, the safety profile of pitavastatin is favorable and appears to be similar to those of other statins. Given its encouraging pharmacokinetic and pharmacodynamic characteristics, pitavastatin is likely to be a good alternative to other more established statins. The pharmacologic and pharmacokinetic properties of pitavastatin are reviewed in this article.

Original languageEnglish (US)
Pages (from-to)264-267
Number of pages4
JournalCardiology in Review
Volume18
Issue number5
DOIs
StatePublished - Sep 2010

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Hypercholesterolemia
Therapeutics
Pharmacokinetics
Lipids
Drug Approval
pitavastatin
Pravastatin
Simvastatin
United States Food and Drug Administration
Dyslipidemias
Drug Interactions
Pharmaceutical Preparations
LDL Cholesterol
Cytochrome P-450 Enzyme System
Isoenzymes
Oxidoreductases
Cholesterol
Safety

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Pitavastatin : A new HMG-CoA reductase inhibitor for the treatment of hypercholesterolemia. / Ahmad, Haniyyah; Cheng-Lai, Angela.

In: Cardiology in Review, Vol. 18, No. 5, 09.2010, p. 264-267.

Research output: Contribution to journalArticle

@article{878325d0247a4d5a84d730ca9c44b911,
title = "Pitavastatin: A new HMG-CoA reductase inhibitor for the treatment of hypercholesterolemia",
abstract = "Because of their good tolerability and their positive effect on lipid parameters and clinical outcomes, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) have become the drugs of first choice for the management of dyslipidemia. Pitavastatin is the newest member in the statin family and received Food and Drug Administration approval for oral use in August 2009. Compared to other statins such as atorvastatin, simvastatin and pravastatin at specific doses, pitavastatin dosed at 1 to 4 mg daily showed similar efficacy in lowering low-density lipoprotein cholesterol (LDL-C) and altering other lipid parameters according to a number of studies. In addition, pitavastatin demonstrated cholesterol-lowering efficacy in special populations such as the elderly, patients with diabetes, and patients with higher cardiovascular risk. Because pitavastatin is minimally metabolized by the cytochrome P-450 isoenzymes, it is associated with a lower frequency of drug-drug interactions, and this may be a desirable characteristic of pitavastatin. Beneficial effects, such as reductions of coronary plaque volume and fibrofatty composition, have also been observed with pitavastatin. Thus far, the safety profile of pitavastatin is favorable and appears to be similar to those of other statins. Given its encouraging pharmacokinetic and pharmacodynamic characteristics, pitavastatin is likely to be a good alternative to other more established statins. The pharmacologic and pharmacokinetic properties of pitavastatin are reviewed in this article.",
author = "Haniyyah Ahmad and Angela Cheng-Lai",
year = "2010",
month = "9",
doi = "10.1097/CRD.0b013e3181ebdb2f",
language = "English (US)",
volume = "18",
pages = "264--267",
journal = "Cardiology in Review",
issn = "1061-5377",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Pitavastatin

T2 - A new HMG-CoA reductase inhibitor for the treatment of hypercholesterolemia

AU - Ahmad, Haniyyah

AU - Cheng-Lai, Angela

PY - 2010/9

Y1 - 2010/9

N2 - Because of their good tolerability and their positive effect on lipid parameters and clinical outcomes, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) have become the drugs of first choice for the management of dyslipidemia. Pitavastatin is the newest member in the statin family and received Food and Drug Administration approval for oral use in August 2009. Compared to other statins such as atorvastatin, simvastatin and pravastatin at specific doses, pitavastatin dosed at 1 to 4 mg daily showed similar efficacy in lowering low-density lipoprotein cholesterol (LDL-C) and altering other lipid parameters according to a number of studies. In addition, pitavastatin demonstrated cholesterol-lowering efficacy in special populations such as the elderly, patients with diabetes, and patients with higher cardiovascular risk. Because pitavastatin is minimally metabolized by the cytochrome P-450 isoenzymes, it is associated with a lower frequency of drug-drug interactions, and this may be a desirable characteristic of pitavastatin. Beneficial effects, such as reductions of coronary plaque volume and fibrofatty composition, have also been observed with pitavastatin. Thus far, the safety profile of pitavastatin is favorable and appears to be similar to those of other statins. Given its encouraging pharmacokinetic and pharmacodynamic characteristics, pitavastatin is likely to be a good alternative to other more established statins. The pharmacologic and pharmacokinetic properties of pitavastatin are reviewed in this article.

AB - Because of their good tolerability and their positive effect on lipid parameters and clinical outcomes, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) have become the drugs of first choice for the management of dyslipidemia. Pitavastatin is the newest member in the statin family and received Food and Drug Administration approval for oral use in August 2009. Compared to other statins such as atorvastatin, simvastatin and pravastatin at specific doses, pitavastatin dosed at 1 to 4 mg daily showed similar efficacy in lowering low-density lipoprotein cholesterol (LDL-C) and altering other lipid parameters according to a number of studies. In addition, pitavastatin demonstrated cholesterol-lowering efficacy in special populations such as the elderly, patients with diabetes, and patients with higher cardiovascular risk. Because pitavastatin is minimally metabolized by the cytochrome P-450 isoenzymes, it is associated with a lower frequency of drug-drug interactions, and this may be a desirable characteristic of pitavastatin. Beneficial effects, such as reductions of coronary plaque volume and fibrofatty composition, have also been observed with pitavastatin. Thus far, the safety profile of pitavastatin is favorable and appears to be similar to those of other statins. Given its encouraging pharmacokinetic and pharmacodynamic characteristics, pitavastatin is likely to be a good alternative to other more established statins. The pharmacologic and pharmacokinetic properties of pitavastatin are reviewed in this article.

UR - http://www.scopus.com/inward/record.url?scp=77955779222&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955779222&partnerID=8YFLogxK

U2 - 10.1097/CRD.0b013e3181ebdb2f

DO - 10.1097/CRD.0b013e3181ebdb2f

M3 - Article

VL - 18

SP - 264

EP - 267

JO - Cardiology in Review

JF - Cardiology in Review

SN - 1061-5377

IS - 5

ER -